For the second time in as many weeks, the Food and Drug Administration has notified physicians and patients that yet another sartan drug used to treat hypertension has been contaminated with a carcinogenic industrial chemical. The manufacturer of the drug has issued a voluntary recall for a single lot of the medication losartan (potassium hydrochlorothiazide), identified as JB8912.
Only a few months ago, government health authorities in Europe and the U.S. issued recalls for the blood pressure medication valsartan over concerns of the presence of a carcinogenic industrial chemical known as N-nitrosodimethylamine (NDMA).
Last month, the China-based Zhejiang Huahai Pharmaceutical Company informed the European Medicines Agency that one of their products used in the treatment of hypertension, known as valsartan, had been contaminated with a chemical known as N-nitrosodimethylamine (NDMA). This substance is a known carcinogen that is used by researchers to intentionally produce cancer in laboratory rats.